marked.bio

Company

SmartNuclide Biopharma

3 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

3 of 3 trials shown

  1. A IIT Study of 177Lu-DOTA-SNA040

    Recruiting Early Phase 1 SmartNuclide Biopharma Started 2025Primary completion 2025-11 NCT07595237

    177Lu-DOTA-SNA040

    At least one lesion must be immunohistochemistry positive for Claudin18.2 (≥ 20% of tumor cells have Claudin18.2 immunohistochemistry membrane staining intensity ≥…

    Claudin 18.2 expressionAdvanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction), Advanced Solid Tumors (Such as Pancreatic Cancer), Advanced Solid Tumors (Such as Cholangiocarcinoma)

  2. Preliminary Trial of SNA014 for Pancreatic Cancer

    Recruiting Early Phase 1 SmartNuclide Biopharma Started 2025Primary completion 2026-07 NCT07597772

    68Ga-NODAGA-SNA006

    A Clinical Study on the Use of ⁶⁸Ga-labelled Claudin 18.2 as a Contrast Agent in Combination With PET/CT for the Imaging of Pancreatic Cancer

    Claudin 18.2 expressionPancreatic Cancer

  3. Phase IIT Trial of SNA014

    Not yet recruiting Early Phase 1 SmartNuclide Biopharma Started 2024Primary completion 2025-10 NCT06646783

    [68Ga]Ga-NODAGA-SNA014

    Pathological test results and Claudin18.2 immunohistochemistry results within the past year (if available).

    Claudin 18.2 expressionStatus may be outdated, last updated 2024-10-17Adenocarcinoma of the Stomach, Adenocarcinoma of GE Junction, Pancreatic Cancer Stage